UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Attralus Receives FDA Orphan Drug Designation for Zamubafusp Alfa in AL Amyloidosis

Source
chemxpert

FDA Grants Orphan Drug Designation to Zamubafusp Alfa

Attralus, a clinical-stage biopharmaceutical company focused on systemic amyloidosis, has announced an important regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zamubafusp alfa (AT-02) for the treatment of immunoglobulin light-chain-associated (AL) amyloidosis.

This designation highlights the potential of zamubafusp alfa as a treatment option for a rare and serious disease that currently has limited therapeutic choices available for patients.